Bluejay Diagnostics, Inc.

Nasdaq:BJDX

Surgical & Medical Instruments & Apparatus·ACTON, MA

CEO

Dey Indranil

Summary Financials

Revenue

$249,040

+0.0% YoY

FY 2023

Adj. EBITDA

-$7.0M

-2820.4% margin

FY 2025

Net Income

-$7.7M

-3099.0% margin

FY 2025

EPS (Diluted)

-$456.75

FY 2025

Stock Price

$2.03

+4.4%

2026-03-11

52W Range

$1.70 – $40.80

P/E Ratio

-0.0x

Market Cap

$2.0M

Cash

$4.3M

FY 2025

Total Debt

$14,725

FY 2021

Net Cash

$4.3M

FY 2021

Enterprise Value

-$2.3M

Debt / EBITDA

0.6x

FY 2023

EV / EBITDA

0.3x

Employees

—

Revenue

$249,040

+0.0% YoY

FY 2023

Adj. EBITDA

-$7.0M

-2820.4% margin

FY 2025

Net Income

-$7.7M

-3099.0% margin

FY 2025

EPS (Diluted)

-$456.75

FY 2025

Stock Price

$2.03

+4.4%

2026-03-11

52W Range

$1.70 – $40.80

P/E Ratio

-0.0x

Market Cap

$2.0M

Cash

$4.3M

FY 2025

Total Debt

$14,725

FY 2021

Net Cash

$4.3M

FY 2021

Enterprise Value

-$2.3M

Debt / EBITDA

0.6x

FY 2023

EV / EBITDA

0.3x

Employees

—